0001437749-22-009234.txt : 20220419
0001437749-22-009234.hdr.sgml : 20220419
20220419171811
ACCESSION NUMBER: 0001437749-22-009234
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220418
FILED AS OF DATE: 20220419
DATE AS OF CHANGE: 20220419
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cobuzzi Robert Joseph Jr.
CENTRAL INDEX KEY: 0001799838
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37942
FILM NUMBER: 22835651
MAIL ADDRESS:
STREET 1: C/O DIFFUSION PHARMACEUTICALS INC.
STREET 2: 1317 CARLTON AVENUE, SUITE 200
CITY: CHARLOTTESVILLE
STATE: VA
ZIP: 22902
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Diffusion Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001053691
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 300645032
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 EAST MAIN STREET
STREET 2: SUITE 201
CITY: CHARLOTTESVILLE
STATE: VA
ZIP: 22902
BUSINESS PHONE: (434) 220-0718
MAIL ADDRESS:
STREET 1: 300 EAST MAIN STREET
STREET 2: SUITE 201
CITY: CHARLOTTESVILLE
STATE: VA
ZIP: 22902
FORMER COMPANY:
FORMER CONFORMED NAME: RestorGenex Corp
DATE OF NAME CHANGE: 20140307
FORMER COMPANY:
FORMER CONFORMED NAME: Stratus Media Group, Inc
DATE OF NAME CHANGE: 20080722
FORMER COMPANY:
FORMER CONFORMED NAME: FERIS INTERNATIONAL, INC.
DATE OF NAME CHANGE: 20080228
4
1
rdgdoc.xml
FORM 4
X0306
4
2022-04-18
0001053691
Diffusion Pharmaceuticals Inc.
DFFN
0001799838
Cobuzzi Robert Joseph Jr.
300 E. MAIN ST. SUITE 201
CHARLOTTESVILLE
VA
22902
1
1
President & CEO
Common Stock
2022-04-18
4
C
0
100
25
A
792
D
Series C Convertible Preferred Stock
25
2022-04-18
4
C
0
100
25
D
Common Stock
100
0
D
As previously announced, on March 18, 2022, the Reporting Person purchased 100 shares of Series C Convertible Preferred Stock, par value $0.001 per share (the "Series C Shares"), from the Issuer at a purchase price of $25.00 per Series C Share in a private placement. On April 18, 2022, in accordance with Section 8(a) of the Certificate of Designation of Preferences, Rights, and Limitations of the Series C Convertible Preferred Stock (the "Certificate of Designation"), the Issuer delivered to the Reporting Person written notice of the Mandatory Conversion (as defined in the Certificate of Designations) of all outstanding Series C Shares into an equivalent number of shares of the Company's common stock, par value $0.001, pursuant to and in accordance with the terms of the Certificate of Designation.
All share and per share amounts have been adjusted to reflect the Issuer's 1-for-50 reverse stock split, effective April 18, 2022.
/s/ William R. Elder, attorney-in-fact for the Reporting Person
2022-04-19